Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 16/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74656 | 0.81 | HRH3 (0.48) | KCNH2 | |
| SCHEMBL74515 | 0.79 | HRH3 (0.46) | KCNH2 | |
| SCHEMBL7960130 | 0.66 | NPY1R (0.70) | NPY1R | |
| SCHEMBL935709 | 0.65 | NPY1R (0.50) | NPY1RSLC6A2SLC6A4 | |
| SCHEMBL7956507 | 0.65 | ITGB3 (0.46) | NPY1RSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL935234 | 0.65 | NPY1R (0.50) | NPY1RSLC6A2SLC6A4 | |
| SCHEMBL74060 | 0.65 | HRH3 (0.52) | KCNH2 | |
| SCHEMBL15281969 | 0.63 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7958522 | 0.63 | NPY1R (0.68) | NPY1R | |
| SCHEMBL75417 | 0.63 | HRH3 (0.50) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | HRH3, HCRTR1, HCRTR2 | NPY1R 120/4885SLC6A2 212/4885SLC6A4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.